Participants will match immunotherapy options to specific biomarkers. Key Features: ● Matching game: Linking biomarkers with corresponding immunotherapy treatments. ● Decision-making process: Selecting personalized treatments and justifying choices. ● Immediate feedback: Clarifications on correct and incorrect matches.
Course Accreditations
This activity is supported with Independent Medical Education Grants from: Exact Sciences Pfizer Puma Biotechnology Novartis 0.75 AMA PRA Category 1 Credit™ The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission. 0.75 Nursing Contact Hours Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours. 0.75 ABIM MOC II Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Course Summary
| Events Starts | Events Ends |
|---|---|
| 3/12/2025 | 3/12/2025 |
- Medical oncologists
- Radiation oncologists
- Surgical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
Target Audience
- Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
- Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
- Explain the role, including advantages and disadvantages, of different testing methodologies available for a selection of targeted therapies.
- Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
- Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in a clinical investigation for cancer patients.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: